Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, discusses experience with biosimilar pegfilgrastim so far.
Transcript
So we’ve already seen 2 biosimilars come to market. We have Udenyca and Fulphila, both drugs are FDA approved for the current indication for pegfilgrastim this setting. So we've seen the actual market start to develop. A lot of discussion has been utilized. We’ve seen some quick implementation for Fulphila and also Udenyca; many sites across the country are transitioning towards that, but also what’s going to actually be distinguished in this discussion is we’re also seeing payers put those biosimilars as a first-line suggestion for therapies in terms of not using the brand-name product.
As you move forward with these pieces, which payers will define what type of biosimilar they use or what maybe their step edits will be for treatment, then it will actually be up to the site or institution to put them in stock.
So if we actually see the emergence of 4, 5, 6 biosimilar pegfilgrastims in the market shortly, the problem will be, will each payer define what type of biosimilar they’ll use? That's going to be very tough for us or any institution any of our [Association of Community Cancer Center, ACCC] members out there, any of our cancer centers. They'll have to stock each one and figure out what type of biosimilar to use per patient.
What makes it worse, or even more confounding, is the amount of time that needs to be noted for that. For the technician, the buyer in this case, but also if you have maybe 5 different companies making biosimilars, and then you have 10 biosimilar lines—a rituximab, and Avastin, a Herceptin, you may have your short-acting growth factor and long-acting growth factor—you start to name these therapies as they evolve, if payers don't actually have a more concise attitude or discussion point for these biosimilars, it will make it very tough to address what pegfilgrastim you have, or if you need to carry many other pieces of that as well.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.